Data / Drug companies / Seton Pharmaceuticals
Seton Pharmaceuticals: 14 products in the FDA NDC directory, labeler code 13925
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Seton Pharmaceuticals (labeler code 13925) lists 14 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 14 prescription drugs. Its main marketing category is other unapproved drugs. The newest product started marketing on March 2, 2022.
The request: Watch Seton Pharmaceuticals (FDA labeler code 13925): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 13925
- Products in commercial distribution
- 14
- Packages
- 16
- Finished drugs by generic name
- 6
- Prescription products
- 14
- Over the counter products
- 0
- Controlled substance products
- Schedule III 2
- Flagged as original packager
- 14 of 14 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- July 1, 2009
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Other unapproved drugs | 8 | 57.1% |
| Generic drugs (ANDA) | 5 | 35.7% |
| New drug applications (NDA) | 1 | 7.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 14 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lidocaine hydrochloride and hydrocortisone acetate | 4 | 2 |
| Butalbital, acetaminophen and caffeine | 2 | 23 |
| Pentamidine isethionate | 2 | 5 |
| Prednisolone sodium phosphate | 1 | 16 |
| Lidocaine hydrochloride | 1 | 134 |
| Memantine hydrochloride oral | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Cream | 4 | 28.6% |
| Solution | 2 | 14.3% |
| Capsule | 2 | 14.3% |
| Gel | 1 | 7.1% |
| Tablet, chewable | 1 | 7.1% |
| Capsule, gelatin coated | 1 | 7.1% |
| Injection, powder, lyophilized, for solution | 1 | 7.1% |
| Tablet | 1 | 7.1% |
| Inhalant | 1 | 7.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Butalbital, acetaminophen and caffeine | 13925-536 | Capsule | Generic drugs (ANDA) | March 2, 2022 |
| Butalbital, acetaminophen and caffeine | 13925-535 | Capsule | Generic drugs (ANDA) | March 2, 2022 |
| Memantine Hydrochloride | 13925-540 | Solution | Generic drugs (ANDA) | August 31, 2020 |
| Pentamidine Isethionate | 13925-522 | Inhalant | Generic drugs (ANDA) | October 14, 2019 |
| Pentamidine Isethionate | 13925-515 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 1, 2018 |
| Prednisolone Sodium Phosphate | 13925-166 | Solution | New drug applications (NDA) | October 18, 2013 |
| Lidocaine Hydrochloride | 13925-159 | Cream | Other unapproved drugs | June 20, 2011 |
| Lidocaine Hydrochloride and Hydrocortisone Acetate | 13925-165 | Cream | Other unapproved drugs | June 17, 2011 |
| Lidocaine Hydrochloride and Hydrocortisone Acetate | 13925-164 | Gel | Other unapproved drugs | June 17, 2011 |
| Lidocaine Hydrochloride and Hydrocortisone Acetate | 13925-163 | Cream | Other unapproved drugs | June 17, 2011 |
| Lidocaine Hydrochloride and Hydrocortisone Acetate | 13925-160 | Cream | Other unapproved drugs | June 17, 2011 |
| Se-Tan PLUS | 13925-118 | Capsule, gelatin coated | Other unapproved drugs | October 1, 2009 |
| Se-Natal 19 Chewable | 13925-117 | Tablet, chewable | Other unapproved drugs | July 1, 2009 |
| Se-Natal 19 | 13925-116 | Tablet | Other unapproved drugs | July 1, 2009 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.